These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22564130)

  • 41. [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI].
    Lems WF; Kuipers EJ
    Ned Tijdschr Geneeskd; 2010; 154(45):A2663. PubMed ID: 21118596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.
    Szeto CC; Sugano K; Wang JG; Fujimoto K; Whittle S; Modi GK; Chen CH; Park JB; Tam LS; Vareesangthip K; Tsoi KKF; Chan FKL
    Gut; 2020 Apr; 69(4):617-629. PubMed ID: 31937550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
    Yeomans ND
    BMC Med; 2015 Mar; 13():56. PubMed ID: 25858463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Questionnaire on NSAID gastropathy among Dutch rheumatologists.
    Steen KS; Lems WF; Dijkmans BA
    Clin Rheumatol; 2000; 19(3):193-4. PubMed ID: 10870652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study
.
    Han MH; Nam JH; Noh E; Lee EK
    Int J Clin Pharmacol Ther; 2019 Nov; 57(11):531-541. PubMed ID: 31397273
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
    Moodley I
    Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of nonsteroidal anti-inflammatory agents on the gastrointestinal tract].
    Bures J; Rejchrt S; Kopácová M; Siroký M
    Cas Lek Cesk; 2002 Oct; 141(21):673-9. PubMed ID: 12564374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current state of therapy for pain and inflammation.
    Abramson SB; Weaver AL
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S1-6. PubMed ID: 16168076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs.
    Peura DA; Goldkind L
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S7-13. PubMed ID: 16168079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies.
    Hollander D
    Am J Med; 1994 Mar; 96(3):274-81. PubMed ID: 8154516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.
    Gabriel SE; Jaakkimainen L; Bombardier C
    Ann Intern Med; 1991 Nov; 115(10):787-96. PubMed ID: 1834002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SHORT- AND LONG-TERM EFFECTS OF NSAIDS ON THE GASTROINTESTINAL MUCOSA: COMPLEX ANALYSIS OF BENEFITS AND COMPLICATIONS PREVENTION.
    Hnepa YY; Chopey IV; Chubirko KI; Bratasyuk AM
    Wiad Lek; 2021; 74(4):1011-1018. PubMed ID: 34156022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications.
    Peura DA
    Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Adherence with proton pump inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs].
    Pimanov SI; Makarenko EV; Dikareva EA
    Ter Arkh; 2015; 87(4):58-61. PubMed ID: 26087636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GI risk and risk factors of NSAIDs.
    Laine L
    J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S60-6. PubMed ID: 16785831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.